Comparative Pharmacology
Head-to-head clinical analysis: ICLUSIG versus INLYTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ICLUSIG versus INLYTA.
ICLUSIG vs INLYTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
45 mg orally once daily with or without food.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing.
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor